Andrew K. Balo, EVP, Reg. Strategy, Clinical at DEXCOM INC (DXCM), sold 8,000 shares at $142.13 ($1.1M) on 2018-11-14, disclosed to the SEC on 2018-11-16.
Seasonal sale ($1.1M) by EVP, Reg. Strategy, Clinical — this insider has traded DXCM in November in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $141.25 | 1,200 | $170K | 14.8% |
| 2 | $142.13 | 800 | $114K | 9.9% |
| 3 | $143.88 | 1,502 | $216K | 18.8% |
| 4 | $143.88 | 1,502 | $216K | 18.8% |
| 5 | $144.43 | 1,498 | $216K | 18.8% |
| 6 | $144.43 | 1,498 |
| $216K |
| 18.8% |
| Total | $143.52 avg | 8,000 | $1.1M | 100% |
| Filing → |
| DXCM | SELL | 2021-07-08 | $2.4M | — | Filing → |
| DXCM | SELL | 2021-06-07 | $897K | — | Filing → |
| DXCM | SELL | 2021-03-12 | $4.0M | — | Filing → |